BLFS Biolife Solutions Inc
- Stocks
- Healthcare
- NASDAQ: BLFS
Price (delayed)
$25.18
Market cap
$1.21B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.54
Enterprise value
$1.2B
BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage
Highlights
BLFS's net income has surged by 93% year-on-year and by 47% since the previous quarter
The EPS has surged by 71% year-on-year and by 18% since the previous quarter
BLFS's quick ratio has soared by 92% year-on-year but it is down by 8% since the previous quarter
BLFS's gross margin is down by 11% year-on-year
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.biolifesolutions.com
Key stats
What are the main financial stats of BLFS
Market
Valuations
Earnings
Shares outstanding
47.91M
Market cap
$1.21B
Enterprise value
$1.2B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.45
Price to sales (P/S)
15.65
EV/EBIT
N/A
EV/EBITDA
2,460.3
EV/Sales
15.66
Revenue
$76.51M
Gross profit
$56.79M
Operating income
-$18.03M
Net income
-$5.53M
EBIT
-$6.72M
EBITDA
$487,000
Free cash flow
$641,000
Per share
Balance sheet
Liquidity
EPS
-$0.54
EPS diluted
-$0.54
Free cash flow per share
$0.01
Book value per share
$7.3
Revenue per share
$1.61
TBVPS
$3.51
Total assets
$387.24M
Total liabilities
$40.09M
Debt
$23.82M
Equity
$347.16M
Working capital
$97.12M
Debt to equity
0.07
Current ratio
4.43
Quick ratio
3.24
Net debt/EBITDA
-16.61
Margins
Efficiency
Dividend
EBITDA margin
0.6%
Gross margin
74.2%
Net margin
-7.2%
Operating margin
-23.6%
Return on assets
-1.4%
Return on equity
-1.6%
Return on invested capital
-6.1%
Return on capital employed
-1.9%
Return on sales
-8.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLFS stock price
How has the Biolife Solutions stock price performed over time
Intraday
-1.95%
1 week
22%
1 month
14.35%
1 year
-2.78%
YTD
-3%
QTD
16.9%
Financial performance
How have Biolife Solutions's revenue and profit performed over time
Revenue
$76.51M
Gross profit
$56.79M
Operating income
-$18.03M
Net income
-$5.53M
Gross margin
74.2%
Net margin
-7.2%
The net margin has surged by 95% year-on-year and by 51% since the previous quarter
BLFS's net income has surged by 93% year-on-year and by 47% since the previous quarter
BLFS's operating income has shrunk by 67% YoY
The company's revenue rose by 38% YoY and by 8% QoQ
Price vs fundamentals
How does BLFS's price correlate with its fundamentals
Growth
What is Biolife Solutions's growth rate over time
Valuation
What is Biolife Solutions stock price valuation
P/E
N/A
P/B
3.45
P/S
15.65
EV/EBIT
N/A
EV/EBITDA
2,460.3
EV/Sales
15.66
The EPS has surged by 71% year-on-year and by 18% since the previous quarter
BLFS's price to book (P/B) is 10% higher than its 5-year quarterly average of 3.2 and 10% higher than its last 4 quarters average of 3.2
The equity has grown by 8% YoY
The company's revenue rose by 38% YoY and by 8% QoQ
The P/S is 11% higher than the 5-year quarterly average of 14.4 and 3.6% higher than the last 4 quarters average of 15.4
Efficiency
How efficient is Biolife Solutions business performance
The ROE has soared by 93% YoY and by 48% from the previous quarter
Biolife Solutions's return on assets has surged by 93% YoY and by 48% QoQ
The return on sales has surged by 93% year-on-year and by 42% since the previous quarter
The ROIC has soared by 89% YoY and by 40% from the previous quarter
Dividends
What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLFS.
Financial health
How did Biolife Solutions financials performed over time
BLFS's quick ratio has soared by 92% year-on-year but it is down by 8% since the previous quarter
BLFS's current ratio has surged by 55% year-on-year but it is down by 6% since the previous quarter
The debt is 93% smaller than the equity
Biolife Solutions's debt to equity has decreased by 36% YoY and by 13% from the previous quarter
The debt has declined by 34% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.